Wire · opportunities
FDA approves first interchangeable ranibizumab biosimilar Ranluspec
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
The US FDA approved Ranluspec, the first interchangeable ranibizumab biosimilar with dual-presentation forms, for treating key retinal conditions. This approval enables pharmacist substitution without prescriber intervention, potentially improving treatment access for conditions like wet AMD.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now position yourself in the US retinal treatment market where pharmacists can swap Lucentis for Ranluspec without extra approvals. This opens paths to streamline supply in eye care clinics and challenges existing brands on pharmacies’ shelves.
◆ Coverage
1 source · 4 Aug 2026
◆ Related on Wire
◆ Topics